Schedule 13G ownership disclosure
N/A
COMMON STOCK · CUSIP: 09627Y109
Event date: 2025-06-30
- Filing-level shares
- 1,465,036
- Percent of class
- 2.3%
- T. Rowe Price Associates, Inc.
Shares: 1,465,036 · Class: 2.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000589
- Form type
- SCHEDULE 13G/A
- Filer
- Blueprint Medicines Corp
- CIK
- CIK 1597264
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership